You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

The Concept of Prodromal Parkinson’s Disease

Abstract

Parkinson’s disease (PD) is currently clinically defined by a set of cardinal motor features centred on the presence of bradykinesia and at least one additional motor symptom out of tremor, rigidity or postural instability. However, converging evidence from clinical, neuropathological, and imaging research suggests initiation of PD-specific pathology prior to appearance of these classical motor signs. This latent phase of neurodegeneration in PD is of particular relevance in relation to the development of disease-modifying or neuroprotective therapies which would require intervention at the earliest stages of disease. A key challenge in PD research, therefore, is to identify and validate markers for the preclinical and prodromal stages of the illness. Currently, several nonmotor symptoms have been associated with an increased risk to develop PD in otherwise healthy individuals and ongoing research is aimed at validating a variety of candidate PD biomarkers based on imaging, genetic, proteomic, or metabolomic signatures, supplemented by work on tissue markers accessible to minimally invasive biopsies. In fact, the recently defined MDS research criteria for prodromal PD have included combinations of risk and prodromal markers allowing to define target populations of future disease modification trials.

INTRODUCTION

Currently, the diagnosis of Parkinson’s disease (PD) is anchored on clinical criteria, which require the presence of bradykinesia and at least one further motor symptom out of tremor, rigidity or postural instability [1] and pathological studies have shown a strong correlation between the extent of Lewy Body related cell loss in the Substantia Nigra (SN) and the severity of bradykinesia [2]. However, this clinico-pathological concept of PD is challenged by several lines of evidence: Firstly, it has been noted for more than 20 years that nigral cell loss and striatal dopamine depletion progress to an approximate threshold of at least 40% before the first appearance of clinically defining motor signs [2, 3]. Secondly, Braak and colleagues have proposed a staging scheme of PD pathology with initiation of α-synuclein pathology in the caudal brainstem and the olfactory bulb and subsequent spread to the midbrain and eventually the limbic and neocortex [4]. This hypothesis has been extended by multiple studies suggesting early involvement of the peripheral autonomic nervous system in PD [5, 6]. Thirdly, the hypothesis of extra-nigral or even peripheral onset of disease seems to converge with clinical studies showing that PD patients may experience a variety of nonmotor symptoms before the first appearance of classical motor signs [7–9]. Indeed, hyposmia, constipation, depression and idiopathic REM Sleep Behaviour Disorder (RBD) have been shown to go along with a significantly increased risk to develop PD in otherwise healthy subjects in population-based or other cohort studies [10–17]. Taken together, these findings clearly speak to the existence of a stage of PD where affected subjects may be asymptomatic (‘preclinical PD’) or where they may present with a variety of nonmotor symptoms and/or subtle motor signs that do not meet current diagnostic criteria (‘prodromal PD’) [18, 19] (Table 1). Taken by themselves, however, these prodromal features lack specificity and –with the possible exception of RBD –have poor predictive value for PD. The challenge is, therefore, to characterise and validate markers that would enhance specificity and positive predictivity for currently prediagnostic stages of the illness. Here we review the current evidence for potential markers of preclinical or prodromal PD including clinical motor and nonmotor symptoms, neuroimaging measures, genetic susceptibility factors as well as molecular and biopsy biomarkers.

PREDIAGNOSTIC NIGROSTRIATAL DYSFUNCTION IN PD

Neuropathological evidence

Neuronal loss in the SN pars compacta (SNc) associated with Lewy Body pathology is the pathologic hallmark feature of sporadic PD [20]. The extent of nigrostriatal dopaminergic denervation has been shown to correlate with severity of classical motor features of PD, in particular bradykinesia and rigidity[2, 21]. Different from age-related physiological cell loss in the SNc estimated to be in the order of 4 to 5% per decade, attrition of SNc dopaminergic neurons in PD seems to follow an exponential curve with an estimated 45% loss in the first decade of disease [3]. Pathological studies have shown 40–60 % threshold of cell loss in the SNc and 60–70 % striatal dopaminergic depletion before the appearance of motor symptoms meeting current PD criteria and extrapolation of the curves suggested a prediagnostic phase of progressive nigral cell loss of 5 years [2, 3]. Interestingly, incidental Lewy bodies are found in brainstem nuclei in more than 10% of individuals free of PD above age 60 and several lines of evidence argue that they may indicate preclinical stages of PD pathology rather than a by-product of neuronal aging [22, 23]. Clinicopathological studies found reduced nigral cell counts to be associated with increasing signs of subtle motor impairment also in subjects without PD [22, 23]. Individuals with incidental Lewy bodies in the SN and locus coeruleus were found to have loss of neurons in these nuclei as well as loss of tyrosine hydroxylase-positive fibres both in the striatum and epicardial fat which was intermediate between PD and normal controls [24]. Incidental Lewy bodies are also associated with nonmotor signs typically found in PD such as hyposmia [25] or constipation [26], again arguing that their presence may represent a presymptomatic phase of PD.

Nigrostriatal dysfunction in PET/SPECT

Nigrostriatal dopaminergic denervation can be shown using radiotracers that label presynaptic dopaminergic markers such as the striatal dopamine transporters (DAT) as routinely achieved with single-photon emission computed tomography (SPECT) or decarboxylase activity with 18F-Dopa positron emission tomography (PET). DAT imaging is closely correlated with post mortem SN cell counts [27] as well as severity and duration of disease [28] and has therefore been considered not only as a surrogate marker for disease progression, but also as a risk marker for PD [29]. Also, 18F-Dopa PET studies in PD patients have shown faster rates of tracer-uptake decline in earlier versus later disease stages and, in accordance with the pathological post-mortem studies, extrapolation of these exponential curves have led to estimates of prediagnostic PD of approximately 6 years[30–32].

Subtle motor impairment and risk for PD

It has been argued that compensatory mechanisms may effectively counteract nigrostriatal dysfunction at the onset of cellular dysfunction and decline of striatal dopamine, thus delaying the appearance of overt parkinsonism for many years [33, 34]. Although slight motor abnormalities such as reduced arm swing, changes in walking patterns, stiffness, tremor, or bradykinesia may precede clinical PD, such signs, captured by routine clinical assessment for parkinsonism [35], often referred to as subtle motor impairment or mild parkinsonian signs, may be found in as many as 40% of the elderly population [36, 37]. In several studies mild parkinsonian signs have been associated with both other PD risk markers as well as with an increased risk for incident PD itself [16, 37]. These signs, however, are quite unspecific in the general population. This may be different when motor tests are applied to enriched cohorts with an apriori increased risk for PD. Prospective studies in subjects with idiopathic RBD have shown that in those who converted to clinically defined PD, impaired motor performance was detected 6–9 years before diagnosis using the Purdue Pegboard, alternate-t p and timed up-and-go test [38]. Similarly, a more recent study by the same group following 89 idiopathic RBD patients over ten years found a 3.9 fold risk to develop PD, dementia with Lewy-bodies (DLB) or multiple system atrophy (MSA) in those with subtle motor impairment at baseline [14]. Using accelerometry-based evaluation of gait and stance, two cross-sectional studies found altered gait variability [39], trunk acceleration and smoothness of sway [40] under challenging conditions in otherwise asymptomatic LRRK2 mutation carriers and subjects with hyperechogenicity of the SN. Noyce and colleagues used an algorithm based on an online survey to categorise participants according to their putative PDrisk [41] in the definition of their prospective PREDICT-PD study cohort [42]. In a cross-sectional baseline analysis, the 100 highest-risk participants had significantly reduced tapping speed in a novel computer keyboard-tapping task versus the 100 lowest-risk participants [42]. Quantifiable motor tests may therefore eventually become useful as a screening element to select at-risk subjects for further secondary screens with more specific tests like DAT imaging.

EARLY NONMOTOR SYMPTOMS AND THE CONCEPT OF PREMOTOR PD

It is now well recognized that nonmotor symptoms are an integral part of the clinical spectrum of the disease [43–46] and may even antedate the clinical manifestation of cardinal motor features of PD by several years in a substantial proportion of patients[7–9, 47] (Table 2). Considering Braak’s hypothesis that PD pathology first starts in extranigral sites, particularly the olfactory system, lower brainstem and peripheral autonomic nervous system [4, 5, 48], it is intriguing to note that recent clinical studies have found certain nonmotor symptoms such as constipation, dream enacting behaviour, and smell-loss preceding the onset of first motor complaints into time periods that are longer before motor onset as compared to other nonmotor complaints [7, 9].

Hyposmia

Olfactory detection, identification or discrimination deficits have consistently been found in approximately 80% of patients with PD [56, 57]. Although many patients retrospectively report smell loss prior to noting the first motor problems [7, 9], to date there are only two population based studies that have investigated prospective risk for PD in relation to baseline smell function [16, 17]. In the Honolulu-Asia Aging study (HAAS), a large cohort of more than 2000 men of Japanese ancestry was prospectively followed for PD incidence with respect to baseline olfactory performance using the Brief Smell Identification Test (B-SIT) [17]. After adjustment for age and other potential confounders, the odds ratio for incident PD within four years in those with the lowest quartile of B-SIT scores at baseline was 5.2 and 3.1 in the second lowest quartile as compared with the top two quartiles. However, hyposmia was not associated with PD risk beyond four years. Intriguingly, a clinicopathologic study in a subsample from the HAAS, found an association of olfactory dysfunction with incidental Lewy bodies in the SN [25]. Likewise, the PRIPS study, a large population-based cohort study on risk factors for incident PD (see imaging biomarkers), found a relative risk ratio of 6.5 in hyposmic participants over 3 years [16]. More recently, several studies have addressed the potential of hyposmia as a risk marker for PD in subjects with increased apriori risk for PD. For example, two recent prospective cohort studies of idiopathic RBD patients found that baseline olfactory dysfunction predicted incident Lewy body disorders over 5 and more years of follow-up [14, 58].

REM-sleep behavior disorder (RBD)

RBD is a parasomnia clinically characterized by dream-enacting behaviours related to loss of physiological atonia during REM-sleep [59]. The prevalence of idiopathic RBD in the population is not well defined as definite diagnosis requires polysomnography. A commonly cited figure of 0.4% , however, may well be an underestimate [60]. Indeed, when using two validated screening questionnaires in an elderly population-based sample of 476 subjects, we recently found a prevalence of probable RBD of 5–8% in a Caucasian population aged >60 years [61]. In this particular cross sectional study, probable RBD was associated with multiple other nonmotor markers of PD, while polysomnography was not available. Idiopathic RBD is increasingly recognized as a harbinger of neurodegenerative diseases, including not only PD but also other synucleinopathies like DLB or MSA. Several follow-up studies have found that the majority of subjects with idiopathic RBD (>80%) will convert into one of these disorders –most commonly PD or DLB - with extended follow-up over decades [15, 54, 62]. Two recent prospective cohort studies have further substantiated these observations. Postuma and colleagues collected follow-up data in a multicentre sample of 305 patients with idiopathic RBD over up to 6 years and found an overall conversion to neurodegenerative diseases of 33% [63], which was time-dependent at 15% after 2 years, 25% after 3 years, and 41% after 5 years. Conversion to PD or DLB was common (42% and 50% , respectively), while only 8% converted to MSA. Idiopathic RBD patient who converted over the observational period were older, more likely to report a family history of dementia, and more frequently endorsed autonomic and/or motor symptoms on questionnaires compared to those who remained disease free, whereas many baseline characteristics including caffeine and nicotine exposure were not different between these groups [63]. With the aid of thorough testing batteries, conversion from RBD to PD or PD Dementia/DLB appears to be more predictable. One recent prospective study in 89 idiopathic RBD patients found that smell identification loss (hazard ratio (HR) 2.8), abnormal colour vision (HR, 3.1), and subtle motor impairment (HR, 3.9), as well as advanced age (HR, 1.1) and non-use of anti-depressants (HR, 3.5) was associated with conversion to one of these synucleinopathies (including MSA) over the 7.5 year observational period.

Taken together, current evidence shows that RBD is the most specific among the different risk factors for PD (see Table 2) and RBD cohorts seem obvious candidates for future disease-prevention studies for PD. However, the median latency to conversion into clinically defined PD can be as long as 12 to 14 years [15, 54], seriously limiting the feasibility of such trials. Therefore, we recently investigated whether olfactory impairment can predict early conversion to PD or PDD/DLB among 35 idiopathic RBD patients prospectively followed over 5 years [58]. Indeed, abnormal baseline performance on the multidimensional SniffinSticks test assessing odour identification, odour discrimination, and olfactory threshold predicted conversion to a Lewy body disorder with an accuracy of 82.4% , and this was also true for poor performance on the identification subscore only. Based on the findings from this cohort, sample sizes for a hypothetical neuroprotection trial in RBD with conversion to a Lewy body disorders as an endpoint could be reduced by 74–80% for a 5-year trial if idiopathic RBD patients were pretested for baseline olfactory dysfunction. For example, a total of 760 patients with idiopathic RBD versus 188 patients with idiopathic RBD and olfactory dysfunction would be required to have an 80% chance to detect a 30% decrease in the primary outcome measure of conversion to a Lewy body disease [58]. Similar data were also reported by Postuma et al. who found that by excluding idiopathic RBD subjects <55 years of age or using antidepressants reduced estimated sample sizes for 3-year neuroprotection trials with the same outcome measure by ≥25% when further pretesting for olfactory dysfunction, impaired colour vision, or subtle motor impairment and by ≥40% when using combinations of these markers [14].

Constipation

Constipation is common in PD affecting 28–61% of patients [46]. In the Honolulu-Asia Aging study men with bowel movement frequencies of less than once per day had a relative risk for incident PD of at least 2.7 compared to men with more frequent bowel function [10]. The brains of 245 subjects from this cohort were available for post-mortem examination and –consistent with the above finding –there was a significant association of constipation in life with the prevalence of incidental Lewy Bodies in the SN at post-mortem: 24.1% of those who had reported less than 1 bowel movement per day had this pathologic feature as compared to 6.5% of those with bowel movement frequencies of greater than 1 per day [65]. Interestingly, several studies have recently reported on findings of synuclein-immunostaining in the enteric nervous system of PD subjects using colonic biopsies providing a possible link between colonic dysmotility and synuclein-related neurodegeneration in PD [65, 66]. However, specificity for PD seems to be rather low (see below under tissue biomarkers).

Intriguing as these associations are, none of the nonmotor symptoms discussed above in themselves have sufficient specificity to qualify for screening for PD risk in the population. While sensitivity for future PD can be as high as 80% for features like hyposmia or constipation, their specificity is low [47]. Although specificity and predictive value of idiopathic RBD for PD risk are much higher, sensitivity is quite low. In addition, for low prevalence disorders like PD, by definition positive predictive values of any of the features discussed are small and would only be in the order of 50% even for markers of 99% specificity [67]. Therefore, future screening tools to narrow down at-risk populations for PD will likely require the use of multiple markers potentially including imaging and molecular biomarkers.

BIOMARKERS FOR PD

A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention [68]. Several candidate PD biomarkers have emerged over the years and some are already established as useful diagnostic markers, particularly those related to neuroimaging. There is also exciting progress in the field of genetic and other molecular markers and recently also of tissue markers that can be accessed through biopsies.

Imaging biomarkers

Radiotracer imaging

Among various imaging techniques, radiotracer-based functional imaging currently offers the highest degree of accuracy in the diagnostic work-up of patients with early PD [29]. Decreased nigrostriatal dopaminergic function is associated with nonmotor symptoms known to precede PD. In a prospective study of first-degree relatives of PD patients, individuals with an olfactory dysfunction showed a faster decline of DAT binding compared to individuals with normal olfactory function [69]. Moreover, 10% of hyposmic individuals, who also had abnormal DAT binding at baseline, developed PD at 2 years and this figure rose to 12.5% at 5 years of follow-up [49]. Another recent prospective study showed that idiopathic RBD patients exhibited decreased DAT binding and faster rates of DAT-binding decline compared to healthy controls [70]. After 3 years of follow-up, 15% of RBD patients, who also had the lowest DAT binding at baseline, had developed PD. As DAT imaging is invasive, time consuming, and expensive, it would not lend itself for primary screening purposes but rather as a secondary screen in enriched populations, such as those with nonmotor symptoms. A recent report on sequential biomarker assessment of population-based hyposmia screening in a first and DAT imaging in a second step - the Parkinson At-Risk Syndrome (PARS) study -reported decreased radiotracer binding using DAT-SPECT to be present in 11% of hyposmic compared with 1% of normosmic participants [71]. Also male sex and constipation were predictive for a DAT-deficit such that combining these three factors increased the percentage of subjects with a DAT deficit to 40% [71]. In contrast to DAT imaging assessing nigrostriatal function, which is an established imaging method in neurodegenerative parkinsonism, direct visualisation of the neuropathologic process i.e. α-synuclein deposition and related neurodegeneration is not yet possible. In analogy to the Pittsburgh compound-B, an in vivo Aβ ligand labeling amyloid depositions in Alzheimer’s dementia, PET radiotracers specific for α-synuclein are beeing developed [72]. Longitudinal imaging of α-synuclein could particularly be relevant in the context of clinical neuroprotection-trials and serve as a surrogat outcome.

Magnetic resonance imaging

There is limited information as to the potential of magnetic resonance imaging (MRI) to detect brain changes associated with PD risk or prodromal PD. Two studies in patients with idiopathic RBD found alterations in diffusivity measures in the tegmentum of the midbrain and the pontine reticular formation, regions involved in the generation of REM sleep [73, 74]. In a functional MRI study, asymptomatic subjects with a heterozygous Parkin and PINK1 mutation exhibited additional recruitment of supplementary motor areas as an expression of compensatory mechanisms [34]. In early PD significant alterations in various MRI diffusivity measures in the SN [75, 76], olfactory tract [75, 77] and cortex [78] were found compared with healthy controls at a field strength of 1.5 T and at a higher field strength of 3.0 T. Two studies reported a complete separation of early PD patients from controls using fractional anisotropy values in the caudal SN at 3.0 T [76] and in the olfactory tract at 1.5 T [75].

Using T2 *-weighted 7T MRI, a recent study described a hyperintense ovoid area within the dorsolateral border of the otherwise hypointense SN pars compacta consistent with nigrosome 1 in healthy controls [79]. The absence of this feature was highly sensitive and specific for PD. Intriguingly, the presence of this feature assessed with susceptibility weighted imaging (SWI) at 3T distinguished PD patients from healthy controls in another dataset of the same group [80] as well as in our own large cohort of patients with neurodegenerative parkinsonism [81], with a sensitivity and specificity of >90% , respectively (Fig. 1). In the latter study also all included patients with MSA and PSP exhibited this imaging feature (i.e. sensitivity of 100%), indicating that visual assessment of dorsolateral nigral hyperintensity on high-field SWI scans may serve as a new simple diagnostic imaging marker for neurodegenerative parkinsonian disorders [81]. Future studies will have to elucidate whether these or other changes in MRI measures can be visualized in subjects exhibiting other PD risk markers and serve as biomarkers for the premotor stage of the illness.

Transcranial sonography

Over the past 2 decades, there has been considerable interest in the use of transcranial sonography (TCS) in PD— a method which is less expensive, time consuming and more widely available compared to radiotracer or MR imaging [82]. An enlarged echogenic area at the anatomical site of the SN in the mesencephalic scanning plane, termed SN-hyperechogenicity, has consistently been found in at least 82% of PD cases but only in up to 23% of healthy controls [82, 83] (Fig. 1). In PD patients, the SN-echogenic sign is neither related to disease severity nor does it change over time [82, 84] and its longitudinal stability has also been reported in healty controls [85] and idiopathic RBD patients [86]. Although the pathophysiologic underpinnings of this echo feature are not entirely clear, histopathological studies have shown a relation of SN-echogenicity with an increased SN iron and ferritin content [87] as well as with decreased neuromelanin and microglial activation in the SN in healthy subjects [88]. Functional imaging studies demonstrated its association with a decreased 18F-Dopa uptake in healthy controls and SN-hyperechogenicity may therefore represent a surrogate marker of an increased vulnerability of the nigrostriatal dopaminergic system [87, 89, 90]. Whether SN-hyperechogenicity issuitable as a preclinical risk marker for PD in healthy elderly populations has recently been investigated in the PRIPS (Prospective validation of risk markers for the development of parkinsonian syndromes) study, a large population-based cohort study with promising results. Data from the 3- and 5-year follow-up investigations revealed a 17- and 21-fold increased risk of developing clinically defined PD in subjects exhibitingSN-hyperechogenicity compared to those without this echo-signal [16, 91, 92]. Interestingly, in a subset of this cohort, SN-hyperechogenity has even been shown to increase the risk for incident mild parkisonian signs over 5 years by about 2-fold, which increased to a 3-fold risk when combined with hyposmia [93].

By combining the imaging modalities 18F-Dopa PET, MRI, and TCS, one study found that putaminal 18F-Dopa uptake and T2 relaxation times of the SN in control subjects with SN-hyperechogenicity were between the values of PD patients and controls without SN-hyperechogenicity [90]. A recent study assessed a set of biomarkers including SN-echognicity in symptomatic and asymptomatic LRRK2 G2019S mutation carriers as well as in patients with sporadic PD and healthy controls [94]. SN-hyperechogenicity was observed not only in approximately 95% of sporadic and genetic PD cases but also in 85% of asymptomatic LRRK2 G2019S mutation carriers as compared to 15% of healthy controls [94], further substantiating the concept of SN-hyperechogenicity as vulnerability marker of the nigrostriatal dopaminergicsystem.

Genetic biomarkers

The diagnosis of idiopathic PD has become more complex thought the discovery of Mendelian genes which cause monogenic forms of the disease such as autosomal dominant mutations in the SNCA, LRRK2 or VPS35 genes and autosomal recessive Parkin or PINK1 mutations. Taken together these account for a small percentage of PD cases seen in clinical practice, but asymptomatic carriers of dominant PD mutations like LRRK2 are obvious candidates when trying to study the preclinical phase of PD. In addition,several other genes have been identified which contribute to an increased risk for the sporadic form of thedisease [95]. Derived from careful clinical observations of parkinsonism in patients with Gaucher’s disease and their relatives, heterozygous mutation in the glucocerebrosidase (GBA) gene has been found to associate with PD risk with an odds ratio of 5.4 [96]. Penetrance of this mutation seems to be high [97] and the prevalence of GBA mutations in PD populations has been between 3 and 20% in different studies, with the highest rates found in PD patients of Ashkenazi Jewish ancestry [96–99]. Importantly, pathogenic GBA variants are found in 1–3% of the population [96] and are associated with deterioration in clinical markers of PD consistent with prodromal PD [99]. A more recent discovery is the association of mutations in the GTP cyclohydrolase 1 gene, representing the most common cause of DOPA-responsive dystonia, with sporadic PD with an odds ratio of 7.5 [100]. Pathogenic variants of this gene, however, seem to be rather rare in the population. Many more common low-risk susceptibility variants in other loci have only recently been identified and confirmed in large meta-analysis of datasets from genome-wide association studies (GWAS) in PD (Table 3). Although the effects of single genetic susceptibility factors seem to be small with odds ratios for each locus ranging from 0.7 to 1.8, risk profile analysis showed substantial cumulative risk in a comparison of the highest and lowest quintiles of genetic risk with odds ratio of 2.5 (95% CI 2.2–2.8) in one [101] and 3.3 (95% CI 2.6–4.3) in a more recent study [102] (Table 3). Many of the reported genes such as SNCA and LRRK2 are also known to encode for key-player proteins in PD pathogenesis [95]. A dedicated online database has recently been created, where results of all published genetic association studies in PD and meta-analysis are freely available (http://www.pdgene.org) [103]. In addition, a polygenic risk score, consisting of small effect allels, has recently been identified in a discovery GWAS dataset and replicated in 3 independent GWAS datasets [104]. The average polygenic score in patients with an early disease age at onset was significantly higher than in those with a late age at onset [104], substantiating the hypothesis that accumulation of common polygenic alleles with relatively low effect sizes may considerably enhance overall PD risk and anticipate disease onset.

However, the true value of genetic risk scores (GRS) in the prediction of incident ‘sporadic’ PD is currently unknown. A recent study combined a GRS from 30 genetic risk factors with other PD markers using stepwise logistic regression analysis to identify PD cases in the Parkinson Progression Marker Initiative (PPMI) cohort as a training dataset [105]. The final model included GRS, olfactory function, family history of PD, age, and sex and was associated with an excellent separation of PD cases from controls in 5 independent validation cohorts (AUCs >0.92) [105]. When looking at the single markers however, olfactory assessment was most responsible for the explained variance (63%), followed by the GRS (14%), family history (11%), sex (6%), and age (6%) underlining the importance of olfactory testing for clinical and research purposes. Future prospective studies will have to assess the true value of this or similar models for the identification of prodromal PD.

Molecular biomarkers

In addition to the recent genomic discoveries, proteomic markers mostly assessed in the cerebrospinal fluid (CSF) are also subject of great research interest [107]. Alpha-synuclein-related parameters were investigated in CSF of PD patients and control populations, in some studies also in combination with DJ1 (Table 4). Results have been inconsistent, which may be due to various confounders, different methodologies used for specimen collection and analysis and due to a lack of standardized operating procedures [108]. The latter will change with prospective multicentre studies such as PPMI, where 400 newly diagnosed PD patients and 200 healthy controls are undergoing regular CSF and imaging marker assessments in an attempt to identify diagnostic and progression biomarkers [109], as well as premotor and genetic markers in recently added substudies. First results in a cross sectional analysis of a subset of the cohort showed lower levels of Aβ1-42, T-tau, P-tau181, α-synuclein, and T-tau/Aβ 1 - 42 early drug naive PD patients compared with healthy controls with a marked overlap between groups [110]. Also, recent meta-analyses of total a-synuclein in the CSF have found decreased levels compared to healthy controls with, however, substantial overlap resulting in a suboptimal diagnostic accuracy with a good sensitivity of 88% but a poor specificity of 40% for PD [111, 112]. Evaluation of a-synuclein and DJ1 in the plasma has produced conflicting results and may be futile as erythrocytes are the greatest source of these proteins in the blood and the slightest degree of hemolysis considerably influences measurements [113]. Other proteins in the peripheral biofluids have been investigated: Using an unbiased proteomic screening approach, a recent study found 11 plasma proteins to be associated with age at PD onset [114]. Among those, low levels of apolipoprotein A1 (ApoA1), the main component of high density lipoproteins (HDL), correlated with earlier PD onset also in a replication cohort and were furthermore associated with greater putaminal DAT deficit among hyposmic subjects at risk for PD in the PARS cohort [114]. These results have been replicated by the same authors in other cohorts including a subset of the PPMI study, where the same direct association with age at disease onset has been found for HDL levels [115]. ApoA1/HDL would represent a particularly interesting PD risk marker, as it is potentially modifiable by drugs like statins. The latter study did, however, not adjust for cofounders of ApoA1/HDL levels such as statin use [115]. Moreover, studies on the influence of statins on PD risk have been conflicting with some showing a decreased risk [116] and others an increased risk for the disease among statin users [117], the latter being in line with evidence of high total cholesterol and/or low density lipoprotein as a protective factor against PD [118, 119]. Therefore, more experimental and longitudinal clinical and population-basedstudies, thoroughly adjusting for multiple confounders, are warranted before ApoA1/HDL elevating drugs may be tested in prospective clinical neuroprotectiontrials.

Although there are other recent promising advances in molecular biomarker research including the measurement of microRNAs in blood of PD and RBD patients significantly differing from healthy controls [120, 121], there is currently no molecular marker or combination of markers that could reliably show increased risk to develop PD. However, in Alzheimer’s disease, which has a pioneering role in neurodegenerative disease research, such biomarkers have been developed and incorporated in diagnostic guidelines [122]. Given the rapidly advancing biochemical technologies, it is strongly hoped that a premotorbiochemical biomarkers can be discovered in PD-risk populations [123].

Tissue biomarkers

The exact clinocopathological correlations underlying the various NMS in PD or pre-PD are still poorly defined. Orthostatic hypotension and constipation may well be mediated by cardio-sympathetic and vasomotor denervation as well as pathology in the enteric nervous system, respectively. Indeed, recent studies have provided consistent evidence for synuclein-related pathology in the peripheral autonomic nervous system using skin punch biopsies, biopsies of the salivary glands as well as colonic biopsies [131–136]. Biopsy studies of synuclein immunostaing in colonic mucosa and submucosa in PD have produced inconsistent results with some authors reporting differences in the percentage of immunopositive samples in PD versus controls [66, 137, 138] and others finding no difference in the prevalence of synuclein-immunostaining of the enteric nervous system [139]. Differences between studies might be related to differences in tissue preparation, staining techniques and antibodies used [136]. For example a recent study only found possible differences between PD and controls when using antibodies againstphosphorylated α-synuclein [140], but this has again not been the case in another report [139]. In addition, synuclein immunopositivity may depend on the site of specimen collection with higher densities in the rostral as compared to caudal aspects of the gut [136]. A recent study found α-synuclein pathology also in the gastric mucosa of PD patients with a sensitivity of 85% and a specificity of 95% [141]. Interestingly, α-synuclein pathology was identified in some PD patients, in whom gut biopsies were taken up to 8 years prior to a clinical diagnosis of PD [142, 143] and one study has found positive immunostaining for phospho-synuclein in some individuals with RBD but in none of a group of age-matched controls [140]. The specificity of such findings for preclinical or prodromal PD still needs to be defined as there are studies strongly suggesting that α-synuclein is a normal constituent of nerve fibres and ganglionic cells in the enteric nervous system [136, 144]. Two studies have recently reported increased aggregation of phospho-synuclein and fibre loss in autonomic sudomotor and pilomotor fibres in skin punch biopsies in PD patients but not in healthy controls [132, 133]. Another region of potential specimen collection for the detection of peripheral α-synuclein may include the salivary glands; although biopsies of minor salivary glands largely lackα-synuclein depositis [134, 145], pre- and post-mortem studies using submandibular gland tissue have found phosphorylated α-synuclein in most PD cases [134]. While olfactory bulb α-synuclein is highly specific and sensitive for Lewy body disorders [146], a study using peripheral olfactory epithelium failed to detect α-synuclein [147]. Out of all α-synuclein related biopsy markers, specimen from the gastronintestinal tract and the salivary glands appear to be the most promising candidate tissue for detection of PD specific pathology [136].

Related to the findings of PD specific pathology in the gut, it seems important to mention that an altered gut microbiom has recently been identified by two studies in PD patients as compared to controls [148, 149]. A proinflammatory effect of the altered microbiosis has been suggested to trigger enteric synuclein-aggregation and subsequent spread of PD pathology [149, 150]. Further studies will have to look into potential relations and pathophysiological relevance of the microbiome in PD as well as its role for PD risk prediction.

OUTLOOK

There is now converging and compelling evidence for the existence of a latent phase of PD where disease specific molecular events of intracellular α-synuclein misfolding, oligomer and fibril formation are initiated to eventually cause neuronal dysfunction and cell death. For unknown periods of time this process may remain clinically asymptomatic (‘Preclinical PD’) or may cause motor or nonmotor symptoms that are in themselves unspecific and do not meet current diagnostic criteria for PD (‘Prodromal ‘ PD). Recent experimental data strongly suggest that the evolution and clinical progression of PD may be largely driven by cell-to-cell propagation of pathogenic α-synuclein species in the central and also peripheral autonomic nervous system in a prion-like fashion [151, 152]. Therapeutic interventions should therefore ideally target the triggering pathogenic events as early as possible to achieve not only slowing of disease progression but also forestalling of disease onset. This makes early diagnosis a key priority and creates an urgent need for valid PD biomarkers with predictive validity for PD diagnosis. Until now several nonmotor clinical features have been shown to associate with PD risk and the combined occurrence of RBD and hyposmia in otherwise asymptomatic subjects has been shown to associate with the development of clinically defined PD or other Lewy body disorders in a substantial proportion over a relatively short time. While this makes RBD patients a realistic target population for future disease prevention studies of PD, it falls short of defining PD risk at the population level. Combinations of demographic, clinical, genetic and imaging markers have now been tested in large PD samples and also at the population level with promising results regarding diagnostic accuracy as well as definitions of PD risk. Searching for synuclein deposition in nervous tissue that can be obtained with minimal invasive procedures like colonoscopy or skin punch biopsies has so far yielded inconsistent results, but, if further refined, may open up another window into detecting preclinical PD pathology.

Taken together, current evidence strongly supports a paradigm shift in the diagnosis of PD with a new focus on defining prodromal stages of the disease. In fact, a task force of the International Parkinson and Movement Disorder Society (MDS) has very recently developed research criteria for the definition of prodromal PD by combining various risk and prodromal markers [153] with the ultimate goal of designing clinical trials to test interventions for disease prevention in at-risk individuals.

CONFLICT OF INTEREST

The authors report no conflict of interest related to this manuscript.

References

1 

Gibb WR, Lees AJ 1988 The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease J Neurol Neurosurg Psychiatry 51 745 752

2 

Greffard S, Verny M, Bonnet A-M, Beinis J-Y, Gallinari C, Meaume S, Piette F, Hauw J-J, Duyckaerts C 2006 Motor score of the unified Parkinson disease rating scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra Arch Neurol 63 584 588

3 

Fearnley JM, Lees AJ 1991 Ageing and Parkinson’s disease: Substantia nigra regional selectivity Brain 114 Pt 5 2283 2301

4 

Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rüb U 2002 Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages) J Neurol 249 Suppl III/1-5

5 

Del Tredici K, Braak H 2012 Lewy pathology and neurodegeneration in premotor Parkinson’s disease Mov Disord 27 597 607

6 

Dickson DW, Fujishiro H, Orr C, DelleDonne A, Josephs KA, Frigerio R, Burnett M, Parisi JE, Klos KJ, Ahlskog JE 2009 Neuropathology of non-motor features of Parkinson disease Parkinsonism Relat Disord 15 S1 S5

7 

Pont-Sunyer C, Hotter A, Gaig C, Seppi K, Compta Y, Katzenschlager R, Mas N, Hofeneder D, Brücke T, Bayés A, Wenzel K, Infante J, Zach H, Pirker W, Posada IJ, Álvarez R, Ispierto L, De Fábregues O, Callén A, Palasí A, Aguilar M, Martí MJ, Valldeoriola F, Salamero M, Poewe W, Tolosa E 2015 The onset of nonmotor symptoms in Parkinson’s disease (The ONSET PDStudy) Mov Disord 30 229 237

8 

Schrag A, Horsfall L, Walters K, Noyce A, Petersen I 2014 Prediagnostic presentations of Parkinson’s disease in primary care: A case-control study Lancet Neurol 14 57 64

9 

Gaenslen A, Swid I, Liepelt-Scarfone I, Godau J, Berg D 2011 The patients’ perception of prodromal symptoms before the initial diagnosis of Parkinson’s disease MovDisord 26 653 658

10 

Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, Grandinetti a, Blanchette PL, Popper JS, Ross GW 2001 Frequency of bowel movements and the future risk of Parkinson’s disease Neurology 57 456 462

11 

Savica R, Carlin JM, Grossardt BR, Bower JH, Ahlskog JE, Maraganore DM, Bharucha AE, Rocca WA 2009 Medical records documentation of constipation preceding Parkinson disease: A case-control study Neurology 73 1752 1758

12 

Ishihara L, Brayne C 2006 A systematic review of depression and mental illness preceding Parkinson’s disease Acta Neurol Scand 113 211 220

13 

Shiba M, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA 2000 Anxiety disorders and depressive disorders preceding Parkinson’s disease: A case-control study Mov Disord 15 669 677

14 

Postuma RB, Gagnon J-F, Bertrand J-A, Génier Marchand D, Montplaisir JY 2015 Parkinson risk in idiopathic REM sleep behavior disorder: Preparing for neuroprotective trials Neurology 84 1104 1113

15 

Iranzo A, Tolosa E, Gelpi E, Molinuevo JL, Valldeoriola F, Serradell M, Sanchez-Valle R, Vilaseca I, Lomeña F, Vilas D, LLadó A, Gaig C, Santamaria J 2013 Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: An observational cohort study Lancet Neurol 12 443 453

16 

Berg D, Godau J, Seppi K, Behnke S, Liepelt-Scarfone I, Lerche S, Stockner H, Gaenslen A, Mahlknecht P, Huber H, Srulijes K, Klenk J, Fassbender K, Maetzler W, Poewe W 2013 The PRIPS study: Screening battery for subjects at risk for Parkinson’s disease Eur J Neurol 20 102 108

17 

Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, Launer L, White LR 2008 Association of olfactory dysfunction with risk for future Parkinson’s disease Ann Neurol 63 167 173

18 

Stern MB, Lang A, Poewe W 2012 Toward a redefinition of Parkinson’s disease Mov Disord 27 54 60

19 

Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, Goetz CG, Halliday GM, Hardy J, Lang AE, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G 2014 Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease Mov Disord 29 454 462

20 

Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK, Litvan I 2009 Neuropathological assessment of Parkinson’s disease: Refining the diagnostic criteria Lancet Neurol 8 1150 1157

21 

Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ 1997 Which clinical sign of Parkinson’s disease best reflects the nigrostriatal lesion? Ann Neurol 41 58 64

22 

Buchman AS, Shulman JM, Nag S, Leurgans SE, Arnold SE, Morris MC, Schneider JA, Bennett DA 2012 Nigral pathology and parkinsonian signs in elders without Parkinson disease Ann Neurol 71 258 266

23 

Ross GW, Petrovitch H, Abbott RD, Nelson J, Markesbery W, Davis D, Hardman J, Launer L, Masaki K, Tanner CM, White LR 2004 Parkinsonian signs and substantia nigra neuron density in decendents elders without PD Ann Neurol 56 532 539

24 

Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, Josephs KA, Frigerio R, Burnett M, Parisi JR, Ahlskog JE 2008 Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease ActaNeuropathol 115 437 444

25 

Ross GW, Abbott RD, Petrovitch H, Tanner CM, Davis DG, Nelson J, Markesbery WR, Hardman J, Masaki K, Launer L, White LR 2006 Association of olfactory dysfunction with incidental Lewy bodies Mov Disord 21 2062 7

26 

Abbott RD, Ross GW, Petrovitch H, Tanner CM, Davis DG, Masaki KH, Launer LJ, Curb JD, White LR 2007 Bowel movement frequency in late-life and incidental Lewy bodies Mov Disord 22 1581 1586

27 

Kraemmer J, Kovacs GG, Perju-Dumbrava L, Pirker S, Traub-Weidinger T, Pirker W 2014 Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts Mov Disord 29 1767 1773

28 

Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, Oakes D, Seibyl J 2001 [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression Neurology 57 2089 2094

29 

Godau J, Hussl A, Lolekha P, Stoessl AJ, Seppi K 2012 Neuroimaging: Current role in detecting pre-motor Parkinson’s disease Mov Disord 27 634 643

30 

Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ 1998 Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET J Neurol Neurosurg Psychiatry 64 314 319

31 

De La Fuente-Fernández R, Schulzer M, Kuramoto L, Cragg J, Ramachandiran N, Au WL, Mak E, McKenzie J, McCormick S, Sossi V, Ruth TJ, Lee CS, Calne DB, Stoessl AJ 2011 Age-specific progression of nigrostriatal dysfunction in Parkinson’s disease Ann Neurol 69 803 810

32 

Hilker R, Schweitzer K, Coburger S, Ghaemi M, Weisenbach S, Jacobs AH, Rudolf J, Herholz K, Heiss W-D 2005 Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity Arch Neurol 62 378 382

33 

Bezard E, Gross CE, Brotchie JM 2003 Presymptomatic compensation in Parkinson’s disease is not dopamine-mediated Trends Neurosci 26 215 221

34 

Van Nuenen BFL, Van Eimeren T, Van Der Vegt JPM, Buhmann C, Klein C, Bloem BR, Siebner HR 2009 Mapping preclinical compensation in Parkinson’s disease: An imaging genomics approach Mov Disord 24 Suppl 2 S703 S710

35 

Maetzler W, Hausdorff JM 2012 Motor signs in the prodromal phase of Parkinson’s disease Mov Disord 27 627 633

36 

Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM, Evans DA 1996 Prevalence of parkinsonian signs and associated mortality in a community population of older people N Engl J Med 334 71 76

37 

Louis ED, Bennett DA 2007 Mild Parkinsonian signs: An overview of an emerging concept Mov Disord 22 1681 1688

38 

Postuma RB, Lang AE, Gagnon JF, Pelletier A, Montplaisir JY 2012 How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder Brain 135 1860 1870

39 

Mirelman A, Gurevich T, Giladi N, Bar-Shira A, Orr-Urtreger A, Hausdorff JM 2011 Gait alterations in healthy carriers of the LRRK2 G2019S mutation Ann Neurol 69 193 197

40 

Maetzler W, Mancini M, Liepelt-Scarfone I, Müller K, Becker C, van Lummel RC, Ainsworth E, Hobert M, Streffer J, Berg D, Chiari L 2012 Impaired trunk stability in individuals at high risk for Parkinson’s disease PLoS One 7 e32240

41 

Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, Schrag A 2012 Meta-analysis of early nonmotor features and risk factors for Parkinson disease Ann Neurol 72 893 901

42 

Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Knowles CH, Hardy J, Giovannoni G, Nageshwaran S, Osborne C, Lees AJ, Schrag A 2014 PREDICT-PD: Identifying risk of Parkinson’s disease in the community: Methods and baseline results J Neurol NeurosurgPsychiatry 85 31 37

43 

Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E, Cannas A, Ceravolo G, Ceravolo R, Cicarelli G, Gaglio RM, Giglia RM, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrale R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Del Dotto P 2009 The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease Mov Disord 24 1641 1649

44 

Erro R, Picillo M, Vitale C, Amboni M, Moccia M, Longo K, Cozzolino A, Giordano F, Rosa A De, Michele G De, Pellecchia MT, Barone P 2013 Non-motor symptoms in early Parkinson’s disease: A 2-year follow-up study on previously untreated patients J Neurol Neurosurg Psychiatry 84 14 17

45 

Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O’Brien JT, Brooks DJ, Barker RA, Burn DJ 2013 The spectrum of nonmotor symptoms in early Parkinson disease Neurology 80 276 281

46 

Poewe W 2008 Non-motor symptoms in Parkinson’s disease Eur J Neurol 15 14 20

47 

Postuma RB, Aarsland D, Barone P, Burn DJ, Hawkes CH, Oertel W, Ziemssen T 2012 Identifying prodromal Parkinson’s disease: Pre-Motor disorders in Parkinson’s disease Mov Disord 27 617 626

48 

Braak H, Del Tredici K, Rüb U, RaI De Vos, ENH Jansen Steur, Braak E 2003 Staging of brain pathology related to sporadic Parkinson’s disease Neurobiol Aging 24 197 211

49 

Ponsen MM, Stoffers D, Wolters EC, Booij J, Berendse HW 2010 Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson’s disease J Neurol Neurosurg Psychiatry 81 396 399

50 

Postuma RB, Gagnon J-F, Vendette M, Desjardins C, Montplaisir JY 2011 Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder Ann Neurol 69 811 818

51 

Ritz B, Lee P, Lassen CF, Arah OA 2014 Parkinson disease and smoking revisited: Ease of quitting is an early sign of the disease Neurology 83 1396 1402

52 

Moccia M, Erro R, Picillo M, Vassallo E, Vitale C, Longo K, Amboni M, Santangelo G, Palladino R, Nardone A, Triassi M, Barone P, Pellecchia MT 2015 Quitting smoking: An early non-motor feature of Parkinson’s disease? Parkinsonism Relat Disord 21 216 220

53 

Patel AJ, Sarwar AI, Jankovic J, Viswanathan A 2014 Bilateral pallidal deep brain stimulation for X-linked dystonia-parkinsonism World Neurosurg 82 241.e1 241.e4

54 

Schenck CH, Boeve BF, Mahowald MW 2013 Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: A 16-year update on a previously reported series Sleep Med 14 744 748

55 

Abbott RD, Ross GW, White LR, Tanner CM, Masaki KH, Nelson JS, Curb JD, Petrovitch H 2005 Excessive daytime sleepiness and subsequent development of Parkinson disease Neurology 65 1442 1446

56 

Doty RL 2012 Olfactory dysfunction in Parkinson disease Nat Rev Neurol 8 329 339

57 

Haehner A, Boesveldt S, Berendse HW, Mackay-Sim A, Fleischmann J, Silburn PA, Johnston AN, Mellick GD, Herting B, Reichmann H, Hummel T 2009 Prevalence of smell loss in Parkinson’s disease - A multicenter study Parkinsonism Relat Disord 15 490 494

58 

Mahlknecht P, Iranzo A, Högl B, Frauscher B, Müller C, Santamaría J, Tolosa E, Serradell M, Mitterling T, Gschliesser V, Goebel G, Brugger F, Scherfler C, Poewe W, Seppi KSleep Innsbruck Barcelona Group 2015 Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD Neurology 84 654 658

59 

Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW 1986 Chronic behavioral disorders of human REM sleep: A new category of parasomnia Sleep 9 293 308

60 

Gagnon JF, Postuma RB, Mazza S, Doyon J, Montplaisir J 2006 Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases Lancet Neurol 5 424 432

61 

Mahlknecht P, Seppi K, Frauscher B, Kiechl S, Willeit J, Stockner H, Djamshidian A, Nocker M, Rastner V, Defrancesco M, Rungger G, Gasperi A, Poewe W, Högl B 2015 Probable RBD and association with neurodegenerative disease markers: A population-based study Mov Disord 30 1417 1421

62 

Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J 2009 Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder Neurology 72 1296 1300

63 

Postuma RB, Iranzo A, Hogl B, Arnulf I, Ferini-Strambi L, Manni R, Miyamoto T, Oertel W, Dauvilliers Y, Ju Y-E, Puligheddu M, Sonka K, Pelletier A, Santamaria J, Frauscher B, Leu-Semenescu S, Zucconi M, Terzaghi M, Miyamoto M, Unger MM, Carlander B, Fantini M-L, Montplaisir JY 2015 Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: A multicenter study Ann Neurol 77 830 839

64 

Abbott RD, Ross GW, Petrovitch H, Tanner CM, Davis DG, Masaki KH, Launer LJ, Curb JD, White LR 2007 Bowel movement frequency in late-life and incidental Lewy bodies Mov Disord 22 1581 1586

65 

Pouclet H, Lebouvier T, Coron E, Bruley des Varannes S, Rouaud T, Roy M, Neunlist M, Derkinderen P 2012 A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson’s disease Neurobiol Dis 45 305 309

66 

Shannon KM, Keshavarzian A, Mutlu E, Dodiya HB, Daian D, Jaglin JA, Kordower JH 2012 Alpha-synuclein in colonic submucosa in early untreated Parkinson’s disease Mov Disord 27 709 715

67 

Siderowf A, Lang AE 2012 Premotor Parkinson’sdisease: Concepts and definitions Mov Disord 27 608 616

68 

Definitions B, Group W 2001 Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework Clin Pharmacol Ther 69 89 95

69 

Ponsen MM, Stoffers D, Booij J, Van Eck-Smit BLF, Wolters EC, Berendse HW 2004 Idiopathic hyposmia as a preclinical sign of Parkinson’s disease Ann Neurol 56 173 181

70 

Iranzo A, Valldeoriola F, Lomeña F, Molinuevo JL, Serradell M, Salamero M, Cot A, Ros D, Pavía J, Santamaria J, Tolosa E 2011 Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: A prospective study Lancet Neurol 10 797 805

71 

Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek KPARS Investigators 2014 Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study Neurology 83 1739 1746

72 

Eberling JL, Dave KD, Frasier MA 2013 α-synuclein imaging: A critical need for Parkinson’s disease research J Parkinsons Dis 3 565 567

73 

Scherfler C, Frauscher B, Schocke M, Iranzo A, Gschliesser V, Seppi K, Santamaria J, Tolosa E, Högl B, Poewe W 2011 White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: A diffusion-tensor imaging and voxel-based morphometry study Ann Neurol 69 400 407

74 

Unger MM, Belke M, Menzler K, Heverhagen JT, Keil B, Stiasny-Kolster K, Rosenow F, Diederich NJ, Mayer G, Möller JC, Oertel WH, Knake S 2010 Diffusion tensor imaging in idiopathic REM sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other brain regions Sleep 33 767 773

75 

Rolheiser TM, Fulton HG, Good KP, Fisk JD, McKelvey JR, Scherfler C, Khan NM, Leslie RA, Robertson HA 2011 Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson’s disease J Neurol 258 1254 1260

76 

Vaillancourt DE, Prodoehl J, Abraham I, Corcos DM, Zhou XJ, Cornelia CL, Little DM 2009 High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease Neurology 72 1378 1384

77 

Scherfler C, Schocke MF, Seppi K, Esterhammer R, Brenneis C, Jaschke W, Wenning GK, Poewe W 2006 Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson’s disease Brain 129 538 542

78 

Ibarretxe-Bilbao N, Junque C, Marti MJ, Valldeoriola F, Vendrell P, Bargallo N, Zarei M, Tolosa E 2010 Olfactory impairment in Parkinson’s disease and white matter abnormalities in central olfactory areas: A voxel-based diffusion tensor imaging study Mov Disord 25 1888 1894

79 

Blazejewska AI, Schwarz ST, Pitiot A, Stephenson MC, Lowe J, Bajaj N, Bowtell RW, Auer DP, Gowland PA 2013 Visualization of nigrosome 1 and its loss in PD: Pathoanatomical correlation and in vivo 7 T MRI Neurology 81 534 540

80 

Schwarz ST, Afzal M, Morgan PS, Bajaj N, Gowland PA, Auer DP 2014 The “swallow tail” appearance of the healthy nigrosome - a new accurate test of Parkinson’sdisease: A case-control and retrospective cross-sectional MRI study at 3T PLoS One 9 e93814

81 

Reiter E, Mueller C, Pinter B, Krismer F, Scherfler C, Esterhammer R, Kremser C, Schocke M, Wenning GK, Poewe W, Seppi K 2015 Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism Mov Disord 30 1068 1076

82 

Berg D, Gaenslen A 2010 Place value of transcranial sonography in early diagnosis of Parkinson’s disease Neurodegener Dis 7 291 299

83 

Mahlknecht P, Seppi K, Stockner H, Nocker M, Scherfler C, Kiechl S, Willeit J, Schmidauer C, Gasperi A, Rungger G, Poewe W 2013 Substantia nigra hyperechogenicity as a marker for parkinson’s disease: A population-based study Neurodegener Dis 12 212 218

84 

Behnke S, Runkel A, Kassar HAS, Ortmann M, Guidez D, Dillmann U, Fassbender K, Spiegel J 2013 Long-term course of substantia nigra hyperechogenicity in Parkinson’s disease Mov Disord 28 455 459

85 

Mahlknecht P, Stockner H, Nocker M, Kiechl S, Willeit J, Scherfler C, Sojer M, Gasperi A, Rungger G, Poewe W, Seppi K 2012 A follow-up study of substantia nigra echogenicity in healthy adults Mov Disord 27 1196 1197

86 

Iranzo A, Stockner H, Serradell M, Seppi K, Valldeoriola F, Frauscher B, Molinuevo JL, Vilaseca I, Mitterling T, Gaig C, Vilas D, Santamaria J, Högl B, Tolosa E, Poewe W 2014 Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder Mov Disord 29 1774 1780

87 

Berg D, Roggendorf W, Schröder U, Klein R, Tatschner T, Benz P, Tucha O, Preier M, Lange KW, Reiners K, Gerlach M, Becker G 2002 Echogenicity of the substantia nigra: Association with increased iron content and marker for susceptibility to nigrostriatal injury Arch Neurol 59 999 1005

88 

Berg D, Godau J, Riederer P, Gerlach M, Arzberger T 2010 Microglia activation is related to substantia nigra echogenicity J Neural Transm 117 1287 1292

89 

Berg D, Becker G, Zeiler B, Tucha O, Hofmann E, Preier M, Benz P, Jost W, Reiners K, Lange KW 1999 Vulnerability of the nigrostriatal system as detected by transcranial ultrasound Neurology 53 1026 1031

90 

Behnke S, Schroeder U, Dillmann U, Buchholz HG, Schreckenberger M, Fuss G, Reith W, Berg D, Krick CM 2009 Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET Neuroimage 47 1237 1243

91 

Berg D, Seppi K, Behnke S, Liepelt I, Schweitzer K, Stockner H, Wollenweber F, Gaenslen A, Mahlknecht P, Spiegel J, Godau J, Huber H, Srulijes K, Kiechl S, Bentele M, Gasperi A, Schubert T, Hiry T, Probst M, Schneider V, Klenk J, Sawires M, Willeit J, Maetzler W, Fassbender K, Gasser T, Poewe W 2011 Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: A 37-month 3-center study of 1847 older persons Arch Neurol 68 932 937

92 

Berg D, Behnke S, Seppi K, Godau J, Lerche S, Mahlknecht P, Liepelt-Scarfone I, Pausch C, Schneider N, Gaenslen A, Brockmann K, Srulijes K, Huber H, Wurster I, Stockner H, Kiechl S, Willeit J, Gasperi A, Fassbender K, Gasser T, Poewe W 2013 Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson’s disease Mov Disord 28 216 219

93 

Mahlknecht P, Kiechl S, Stockner H, Willeit J, Gasperi A, Poewe W, Seppi K 2015 Predictors for mild parkinsonian signs: A prospective population-based study Parkinsonism Relat Disord 21 321 324

94 

Sierra M, Sánchez-Juan P, Martínez-Rodríguez MI, González-Aramburu I, García-Gorostiaga I, Quirce MR, Palacio E, Carril JM, Berciano J, Combarros O, Infante J 2013 Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease Neurology 80 621 626

95 

Trinh J, Farrer M 2013 Advances in the genetics of Parkinson disease Nat Rev Neurol 9 445 454

96 

Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, Chen C-M, Clark LN, Condroyer C, De Marco EV, Dürr A, Eblan MJ, Fahn S, Farrer MJ, Fung H-C, Gan-Or Z, Gasser T, Gershoni-Baruch R, Giladi N, Griffith a, Gurevich T, Januario C, Kropp P, Lang AE, Lee-Chen G-J, Lesage S, Marder K, Mata IF, Mirelman a, Mitsui J, Mizuta I, Nicoletti G, Oliveira C, Ottman R, Orr-Urtreger A, Pereira LV, Quattrone a, Rogaeva E, Rolfs a, Rosenbaum H, Rozenberg R, Samii a, Samaddar T, Schulte C, Sharma M, Singleton a, Spitz M, Tan E-K, Tayebi N, Toda T, Troiano AR, Tsuji S, Wittstock M, Wolfsberg TG, Wu Y-R, Zabetian CP, Zhao Y, Ziegler SG 2009 Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease N Engl J Med 361 1651 1661

97 

Anheim M, Elbaz A, Lesage S, Durr A, Condroyer C, Viallet F, Pollak P, Bonaïti B, Bonaïti-Pellié C, Brice A 2012 Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers Neurology 78 417 420

98 

Brockmann K, Srulijes K, Pflederer S, Hauser A-K, Schulte C, Maetzler W, Gasser T, Berg D 2015 GBA-associated Parkinson’s disease: Reduced survival and more rapid progression in a prospective longitudinal study Mov Disord 30 407 411

99 

Beavan M, McNeill A, Proukakis C, Hughes DA, Mehta A, Schapira AHV 2015 Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort JAMA Neurol 72 201 208

100 

Mencacci NE, Isaias IU, Reich MM, Ganos C, Plagnol V, Polke JM, Bras J, Hersheson J, Stamelou M, Pittman AM, Noyce AJ, Mok KY, Opladen T, Kunstmann E, Hodecker S, Münchau A, Volkmann J, Samnick S, Sidle K, Nanji T, Sweeney MG, Houlden H, Batla A, Zecchinelli AL, Pezzoli G, Marotta G, Lees A, Alegria P, Krack P, Cormier-Dequaire F, Lesage S, Brice A, Heutink P, Gasser T, Lubbe SJ, Morris HR, Taba P, Koks S, Majounie E, Raphael Gibbs J, Singleton A, Hardy J, Klebe S, Bhatia KP, Wood NW 2014 Parkinson’s disease in GTP cyclohydrolase 1 mutation carriers Brain 137 2480 2492

101 

Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, Saad M, Simón-Sánchez J, Schulte C, Lesage S, Sveinbjörnsdóttir S, Stefánsson K, Martinez M, Hardy J, Heutink P, Brice A, Gasser T, Singleton AB, Wood NW 2011 Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: A meta-analysis of genome-wide association studies Lancet 377 641 649

102 

Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R, International Parkinson’s Disease Genomics Consortium (IPDGC); Parkinson’s Study Group (PSG) Parkinson’s Research: The Organized GENetics Initiative (PROGENI); 23 and Me; GenePD; NeuroGenetics Research Consortium (NGRC); Hussman Institute of Human Genomics (HIHG); Ashkenazi Jewish Dataset Investigator; Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE); North American Brain Expression Consortium (NABEC); United Kingdom Brain Expression Consortium (UKBEC); Greek Parkinson’s Disease Consortium; Alzheimer Genetic Analysis GroupIkram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB 2014 Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease Nat Genet 46 989 993

103 

Lill CM, Roehr JT, McQueen MB, Kavvoura FK, Bagade S, Schjeide BM, Schjeide LM, Meissner E, Zauft U, Allen NC, Liu T, Schilling M, Anderson KJ, Beecham G, Berg D, Biernacka JM, Brice A, DeStefano AL, Do CB, Eriksson N, Factor SA, Farrer MJ, Foroud T, Gasser T, Hamza T, Hardy JA, Heutink P, Hill-Burns EM, Klein C, Latourelle JC, Maraganore DM, Martin ER, Martinez M, Myers RH, Nalls MA, Pankratz N, Payami H, Satake W, Scott WK, Sharma M, Singleton AB, Stefansson K, Toda T, Tung JY, Vance J, Wood NW, Zabetian CP, 23andMe Genetic Epidemiology of Parkinson’s Disease Consortium; International Parkinson’s Disease Genomics Consortium; Parkinson’s Disease GWAS Consortium; Wellcome Trust Case Control Consortium 2)Young P, Tanzi RE, Khoury MJ, Zipp F, Lehrach H, Ioannidis JP, Bertram L 2012 Comprehensive research synopsis and systematic meta-analyses in Parkinson’s disease genetics: The PDgene database PLoS Genet 8 4 13

104 

Escott-Price V, Nalls MA, Morris HR, Lubbe S, Brice A, Gasser T, Heutink P, Wood NW, Hardy J, Singleton AB, Williams NM 2015 Polygenic risk of Parkinson disease is correlated with disease age at onset Ann Neurol 77 582 591

105 

Nalls MA, McLean CY, Rick J, Eberly S, Hutten SJ, Gwinn K, Sutherland M, Martinez M, Heutink P, Williams NM, Hardy J, Gasser T, Brice A, Price TR, Nicolas A, Keller MF, Molony C, Gibbs JR, Chen-Plotkin A, Suh E, Letson C, Fiandaca MS, Mapstone M, Federoff HJ, Noyce AJ, Morris H, Van Deerlin VM, Weintraub D, Zabetian C, Hernandez DG, Lesage S, Mullins M, Conley ED, Northover CA, Frasier M5, Marek K, Day-Williams AG, Stone DJ, Ioannidis JP, Singleton ABParkinson’s Disease Biomarkers Program and Parkinson’s Progression Marker Initiative investigators 2015 Diagnosis of Parkinson’s disease on the basis of clinical and genetic classification: A population-based modelling study Lancet Neurol 14 1002 1009

106 

Pankratz N, Beecham GW, Destefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER, Mayeux R, Ross OA, Scherzer CR, Simon DK, Tanner C, Vance JM, Wszolek ZK, Zabetian CP, Myers RH, Payami H, Scott WK, Foroud T 2012 Meta-analysis of Parkinson’s Disease: Identification of a novel locus, RIT2 Ann Neurol 71 370 384

107 

Parnetti L, Castrioto A, Chiasserini D, Persichetti E, Tambasco N, El-Agnaf O, Calabresi P 2013 Cerebrospinal fluid biomarkers in Parkinson disease Nat Rev Neurol 9 131 140

108 

Del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, Kapaki E, Kruse N, Le Bastard N, Lehmann S, Molinuevo JL, Parnetti L, Perret-Liaudet A, Sáez-Valero J, Saka E, Urbani A, Vanmechelen E, Verbeek M, Visser PJ, Teunissen C 2012 Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: An update Biomark Med 6 419 430

109 

Parkinson ProgressionMarker, Initiative 2011 The Parkinson Progression Marker Initiative (PPMI) Prog Neurobiol 95 629 635

110 

Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LMParkinson’s Progression Markers Initiative 2013 Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease JAMA Neurol 70 1277 1287

111 

Gao L, Tang H, Nie K, Wang L, Zhao J, Gan R, Huang J, Zhu R, Feng S, Duan Z, Zhang Y, Wang L 2015 Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson’s disease diagnosis: A systematic review and meta-analysis Int J Neurosci 125 645 654

112 

Zetterberg H, Petzold M, Magdalinou N 2014 Cerebrospinal fluid α-synuclein levels in Parkinson’s disease–changed or unchanged? Eur J Neurol 21 365 367

113 

Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Leverenz JB, Zhang J 2010 Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson’s disease Neurosci Lett 480 78 82

114 

Qiang JK, Wong YC, Siderowf A, Hurtig HI, Xie SX, Lee VMY, Trojanowski JQ, Yearout D, Leverenz JB, Montine TJ, Stern M, Mendick S, Jennings D, Zabetian C, Marek K, Chen-Plotkin AS 2013 Plasma apolipoprotein A1 as a biomarker for Parkinson disease Ann Neurol 74 119 127

115 

Swanson CR, Berlyand Y, Xie SX, Alcalay RN, Chahine LM, Chen-Plotkin AS 2015 Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson’s disease patients Mov Disord 10.1002/mds.26290

116 

Lee Y, Lin C, Wu R-M, Lin M-S, Lin J-W, Chang C-H, Lai M-S 2013 Discontinuation of statin therapy associates with Parkinson disease: A population-based study Neurology 81 410 416

117 

Huang X, Alonso A, Guo X, Umbach DM, Lichtenstein ML, Ballantyne CM, Mailman RB, Mosley TH, Chen H 2015 Statins, plasma cholesterol, and risk of Parkinson’s disease: A prospective study Mov Disord 30 552 559

118 

Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J 2008 Total cholesterol and the risk of Parkinson disease Neurology 70 1972 1979

119 

Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW 2008 Low LDL cholesterol and increased risk of Parkinson’s disease: Prospective results from Honolulu-Asia Aging Study Mov Disord 23 1013 1018

120 

Serafin A, Foco L, Zanigni S, Blankenburg H, Picard A, Zanon A, Giannini G, Pichler I, Facheris MF, Cortelli P, Pramstaller PP, Hicks AA, Domingues FS, Schwienbacher C 2015 Overexpression of blood microRNAs 103a, 30b, and 29a in L-dopa-treated patients with PD Neurology 84 645 653

121 

Khoo SK, Petillo D, Kang UJ, Resau JH, Berryhill B, Linder J, Forsgren L, Neuman LA, Tan AC 2012 Plasma-based circulating MicroRNA biomarkers for Parkinson’s disease J Parkinsons Dis 2 321 331

122 

McKhann GM 2011 Changing concepts of Alzheimerdisease JAMA 305 2458 2459

123 

Mollenhauer B, Zhang J 2012 Biochemical premotor biomarkers for Parkinson’s disease Mov Disord 27 644 650

124 

Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, Zhang J 2010 DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease Brain 133 713 726

125 

Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, Wang Y, Aasly J, Goldstein D, Zhang J 2011 Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression Ann Neurol 69 570 580

126 

Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG 2011 α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: A cohort study Lancet Neurol 10 230 240

127 

Van Dijk KD, Bidinosti M, Weiss A, Raijmakers P, Berendse HW, van de Berg WDJ 2014 Reduced α-synuclein levels in cerebrospinal fluid in Parkinson’s disease are unrelated to clinical and imaging measures of disease severity Eur J Neurol 21 388 394

128 

Mollenhauer B, Trautmann E, Taylor P, Manninger P, Sixel-Döring F, Ebentheuer J, Trenkwalder C, Schlossmacher MG 2013 Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects Neurosci Lett 532 44 48

129 

Wang Y, Shi M, Chung KA, Zabetian CP, Leverenz JB, Berg D, Srulijes K, Trojanowski JQ, Lee VM-Y, Siderowf AD, Hurtig H, Litvan I, Schiess MC, Peskind ER, Masuda M, Hasegawa M, Lin X, Pan C, Galasko D, Goldstein DS, Jensen PH, Yang H, Cain KC, Zhang J 2012 Phosphorylated alpha-synuclein in Parkinson’s disease Sci Transl Med 4 121ra20-121ra20

130 

Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T, Ishigami N, Tamaoka a, Nakagawa M, El-Agnaf OM 2010 Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease Neurology 75 1766 1772

131 

Wang N, Gibbons CH, Lafo J, Freeman BSR 2013 α-Synuclein in cutaneous autonomic nerves Neurology 81 1604 1610

132 

Doppler K, Ebert S, Üçeyler N, Trenkwalder C, Ebentheuer J, Volkmann J, Sommer C 2014 Cutaneous neuropathy in Parkinson’s disease: A window into brain pathology Acta Neuropathol 128 99 109

133 

Donadio V, Incensi A, Leta V, Giannoccaro MP, Scaglione C, Martinelli P, Capellari S, Avoni P, Baruzzi A, Liguori R 2014 Skin nerve a-synuclein deposits A biomarker for idiopathic Parkinson disease Neurology 82 1362 1369

134 

Adler CH, Dugger BN, Hinni ML, Lott DG, Driver-Dunckley E, Hidalgo J, Henry-Watson J, Serrano G, Sue LI, Nagel T, Duffy A, Shill HA, Akiyama H, Walker DG, Beach TG 2014 Submandibular gland needle biopsy for the diagnosis of Parkinson disease Neurology 82 858 864

135 

Devic I, Hwang H, Edgar JS, Izutsu K, Presland R, Pan C, Goodlett DR, Wang Y, Armaly J, Tumas V, Zabetian CP, Leverenz JB, Shi M, Zhang J 2011 Salivary alpha-synuclein and DJ-1: Potential biomarkers for Parkinson’s disease Brain 134 Pt 7 e178

136 

Schneider SA, Boettner M, Alexoudi A, Zorenkov D, Deuschl G, Wedel T 2015 Can we use peripheral tissue biopsies to diagnose Parkinson’s disease? A review of the literature Eur J Neurol 10.1111/ene.12753

137 

Lebouvier T, Neunlist M, des Varannes SB, Coron E, Drouard A, N’Guyen JM, Chaumette T, Tasselli M, Paillusson S, Flamand M, Galmiche JP, Damier P, Derkinderen P 2010 Colonic biopsies to assess the neuropathology of Parkinson’s disease and its relationship with symptoms PLoS One 5 1 9

138 

Pouclet H, Lebouvier T, Coron E, Des Varannes SB, Neunlist M, Derkinderen P 2012 A comparison between colonic submucosa and mucosa to detect Lewy pathology in Parkinson’s disease Neurogastroenterol Motil 24 202 205

139 

Visanji NP, Marras C, Kern DS, Al Dakheel A, Gao A, Liu LWC, Lang AE, Hazrati L-N 2015 Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease Neurology 84 609 616

140 

Sprenger F, Gelpi E, Navarro-Otano J, Offner F, Vilas D, Valladeoriola F, Pont-Sunyer C, Aldecoa I, Gaig C, Gines A, Cuatrecases M, Hogl B, Frauscher B, Iranzo A, Wenning GK, Vogel W, Tolosa E, Poewe W 2015 Enteric nervous system alpha-synuclein immunoreactivity in idopathic REM sleep behavior disorder Neurology Oct 16. pii:10.1212/WNL.0000000000002126. [Epub ahead of print]

141 

Sánchez-Ferro Á, Rábano A, Catalán MJ, Rodríguez-Valcárcel FC, Fernández Díez S, Herreros-Rodríguez J, García-Cobos E, Álvarez-Santullano MM, López-Manzanares L, Mosqueira AJ, Vela Desojo L, López-Lozano JJ, López-Valdás E, Sánchez-Sánchez R, Molina-Arjona JA 2015 gastric detection of α-synuclein inclusions in Parkinson’s disease Mov Disord 30 517 524

142 

Hilton D, Stephens M, Kirk L, Edwards P, Potter R, Zajicek J, Broughton E, Hagan H, Carroll C 2014 Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson’s disease Acta Neuropathol 127 235 241

143 

Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH 2012 Is alpha-synuclein in the colon a biomarker for premotor Parkinson’s Disease? Evidence from 3 cases Mov Disord 27 716 719

144 

Böttner M, Zorenkov D, Hellwig I, Barrenschee M, Harde J, Fricke T, Deuschl G, Egberts J-H, Becker T, Fritscher-Ravens A, Arlt A, Wedel T 2012 Expression pattern and localization of alpha-synuclein in the human enteric nervous system Neurobiol Dis 48 474 480

145 

Folgoas E, Lebouvier T, Leclair-Visonneau L, Cersosimo M-G, Barthelaix A, Derkinderen P, Letournel F 2013 Diagnostic value of minor salivary glands biopsy for the detection of Lewy pathology Neurosci Lett 551 62 64

146 

Beach TG, White CL, Hladik CL, Sabbagh MN, Connor DJ, Shill HA, Sue LI, Sasse J, Bachalakuri J, Henry-Watson J, Akiyama H, Adler CH 2009 Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders Acta Neuropathol 117 169 174

147 

Witt M, Bormann K, Gudziol V, Pehlke K, Barth K, Minovi A, Hähner A, Reichmann H, Hummel T 2009 Biopsies of olfactory epithelium in patients with Parkinson’s disease Mov Disord 24 906 914

148 

Scheperjans F, Aho V, Pereira PAB, Koskinen K, Paulin L, Pekkonen E, Haapaniemi E, Kaakkola S, Eerola-Rautio J, Pohja M, Kinnunen E, Murros K, Auvinen P 2015 Gut microbiota are related to Parkinson’s disease and clinical phenotype Mov Disord 30 350 358

149 

Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, Mutlu E, Shannon KM 2015 Colonic bacterial composition in Parkinson’s disease Mov Disord 30 1351 1360

150 

Scheperjans F, Pekkonen E, Kaakkola S, Auvinen P 2015 Linking smoking, coffee, urate, and Parkinson’s disease - a role for gut microbiota? J Parkinsons Dis 5 255 262

151 

Angot E, Steiner JA, Hansen C, Li JY, Brundin P 2010 Are synucleinopathies prion-like disorders? Lancet Neurol 9 1128 1138

152 

Woerman AL, Stöhr J, Aoyagi A, Rampersaud R, Krejciova Z, Watts JC, Ohyama T, Patel S, Widjaja K, Oehler A, Sanders DW, Diamond MI, Seeley WW, Middleton LT, Gentleman SM, Mordes DA, Südhof TC, Giles K, Prusiner SB 2015 Propagation of prions causing synucleinopathies in cultured cells Proc Natl Acad Sci U S A 112 E4949 E4958

153 

Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G 2015 MDS research criteria for prodromal Parkinson’s disease Mov Disord 30 1600 1611

Figures and Tables

Fig.1

Midbrain / substantia nigra (SN) imaging with magnetic resonance imaging (MRI) and Transcranial sonography (TCS). A: Susceptibility weighted (SWI) MRI image of a healthy control (HC) at the left column, demonstrating the magnified dorsolateral nigral hyperintensity within the right SN. White arrows mark the dorsolateral nigral hyperintensity in the survey as well as in the magnified illustration. The right column show SWI images of a patient with Parkinson’s disease (PD), demonstrating the absence of the dorsolateral nigral hyperintensity. B: TCS images of mesencaphalic scanning planes showing typically butterfly-shaped mesencephalic brainstems from a HC with a normal midbrain echogenicity in the upper images. A PD patient with an enlarged midbrain echogenicity at the area of the SN (SN-hyperechogenicity) is shown in the lower images.

Midbrain / substantia nigra (SN) imaging with magnetic resonance imaging (MRI) and Transcranial sonography (TCS). A: Susceptibility weighted (SWI) MRI image of a healthy control (HC) at the left column, demonstrating the magnified dorsolateral nigral hyperintensity within the right SN. White arrows mark the dorsolateral nigral hyperintensity in the survey as well as in the magnified illustration. The right column show SWI images of a patient with Parkinson’s disease (PD), demonstrating the absence of the dorsolateral nigral hyperintensity. B: TCS images of mesencaphalic scanning planes showing typically butterfly-shaped mesencephalic brainstems from a HC with a normal midbrain echogenicity in the upper images. A PD patient with an enlarged midbrain echogenicity at the area of the SN (SN-hyperechogenicity) is shown in the lower images.
Table 1

Conceptual stages of Parkinson’s disease

Phases of PDClinical statusPathologyComments
Phase 1 - preclinicalNo clinical signs or symptomsPD-specific pathology assumed to be presentSupported by biomarkers (genetic, molecular, and/or imaging)
Phase 2 - prodromalEarly nonmotor symptoms±early subtle motor symptomsExtranigral PD pathology (Braak stages 1 and 2)±nigral PD pathology (<40–60% cell loss; Braak Stage 3)Criteria yet to be defined based on clinical motor and nonmotor markers and nonclinical biomarkers. Two levels of certainty have been proposed [19]: Probable prodromal PD (high likelihood, e.g., >80% ; sufficiently certain for neuroprotective trials) and possible prodromal PD (lower, but still substantial likelihood, e.g., 30% –80%)
Phase 3 - motorClassical motor manifestations are presentNigral PD pathology (>40–60% cell loss; Braak stages 3 to 6)Current clinical diagnostic criteria based on motor syndrome are met;±a variety on nonmotor symptoms may be present due to the extension of PD pathology

Modified from Stern et al. 2012 [18].

Table 2

Nonmotor symptoms in prodromal PD

Nonmotor

   symptom
May occur prior

      to motor symptoms
Timespan before

   motor onset
Sensitivity for

   future PD
Specificity for

   future PD
Reference
Sensory symptoms
Hyposmia++Medium (up toHigh (>80% PDLow (>30% of elderly[7, 9, 16, 17, 49]
   5–10 years)   patients affected)   have hyposmia)
Visual abnormalities+Unknown (in RBD up to 10 years)UnknownUnknown[14, 50]
   (e.g. reduced colour vision)
Pain+/-
Neuropsychiatric symptoms
Depression and anxiety++Medium (up to 10 years)Low (30–40% Low (common in the[7, 8, 12, 13]
   of PD patients affected)   elderly population)
Anhedonia and apathy+/-[7]
Frontal executive dysfunction+/-
Behavioural symptoms
Quitting smoking+Long (mean 10 years)UnknownUnknown[51, 52]
Autonomic dysfunction
Constipation++Long (potentially moreModerate (30–60% Low (common in the[7–11, 53]
   than 10–20 years)   of PD patients affected)   elderly population)
Orthostatic hypotension+/-[8]
Urogenital dysfunction+/-[8]
Sleep disorders
RBD++Long (potentially moreLow to moderate (30–50% High (>80% of idiopathic[14, 15, 54]
   than 10–20 years)   of PD patients affected)   RBD patients will develop
   Lewy-body disorders)
Excessive daytime somnolence+Medium (up to 5–10 years)UnknownUnknown[7, 55]
Sleep fragmentation and insomnia+/-
PLMS/RLS+/-

Abbreviations: PD, Parkinson’s disease; PLMS, periodic limb movements during sleep; RBD, rapid eye movement sleep behavior disorder; RLS, restless legs syndrome. ++ = robust evidence from more than one prospective population-based or cohort study, + = evidence from one prospective population-based or cohort study or more than one retrospective population-based or cohort study, +/- = no evidence from population based or cohort studies, but respective nonmotor symptom is frequently seen in early PD [43–45].

Table 3

Parkinson’s disease risk genes –evidence from genome genome-wide association studies

StudyDesignSubjectsResults
Nalls et al. 2011 [101]Meta-analysis from 5 GWAS (USA &Europe)Discovery set: 5,333 PD and 12,019 controls; Replication set: 7,053 PD and 9,007 controls•Previously identified loci confirmed: MAPT, SNCA, HLA-DRB5, BST1, GAK and LRRK2
•Newly identified loci: ACMSD, STK39, MCCC1/LAMP3, SYT11, and CCDC62/HIP1R
•Odds ratio of 2.5 (95% CI 2.2–2.8) in the highest versus the lowest quintile of disease risk
Pankratz et al. 2012 [106]Meta-analysis from 5 GWAS (USA)Discovery set: 4,238 PD and 4,239 controls; Replication set: 3,738 PD and 2,111 controls•Association with SNCA, MAPT, GAK/DGKQ, GBA and the HLA region confirmed
•Novel locus RIT2
Lill et al. 2012 [103]Meta-analysis from GWAS and PD association studies (literature screen)Up to 16,452 PD and 48,810 controls (from 828 studies)•Association with BST1, CCDC62/HIP1R, DGKQ/GAK, GBA, LRRK2, MAPT, MCCC1/LAMP3, PARK16, SNCA, STK39, and SYT11/RAB25
•Novel locus ITGA8
•Results freely available on: www.PDGene.org
Nalls et al. 2014 [102]Meta-analysis from multiple GWAS in USA and EurpoeDiscovery set: 13,708 cases and 95,282 controls; Replication set: 5,353 cases and 5,551 controls•Of the 32 SNPs tested in the replication set (26 loci identified in the discovery phase and 6 previously reported loci) 24 were replicated including 6 newly identified loci
•4 loci (GBA, GAK/DGKQ, SNCA and the HLA region) contained a secondary independent risk variant
•Odds ratio of 3.3 (95% CI 2.6–4.3) in the highest versus the lowest quintile of disease risk
Table 4

Selection of studies assessing the potential of a-synuclein- and DJ1-based CSF markers for detecting PD

Marker/StudyChangeSensitivitySpecificityCommentsReferences
   (REF)in PD
Total α-Syn71% –100% 38% –58% [110, 124–128]
91% 25% Studies in early drug-naive PD[110, 128]
Phosphorylated61% 80% For combined phosphorylated and total[129]
α-Syn80% 64%    α-Syn using two different cut-off values
α-Syn75% 88% α-Syn oligomers alone[130]
Oligomers89% 91% Ratio to total α-Syn
DJ190% –97% 50% –70% [124, 125]